This article traces the genesis of Indian patent law with regard to the protection of product patents for medicines, reviews the changes brought by the TRIPS Agreement and India’s measures to become compliant with this international regime, reviews the legal and policy arguments raised in the Novartis case, and discusses the implications of this decision on other developing and least developed countries in terms of access, policy considerations and legislative choices when crafting appropriate laws.

pdfClick to download full-text article